Influence of reproductive factors on mortality after epithelial ovarian cancer diagnosis

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 7, 2009, Pages 2035-2041

  Robbins, Cheryl L ^a,b   Whiteman, Maura K ^b   Hillis, Susan D ^b   Curtis, Kathryn M ^b   McDonald, Jill A ^b   Wingo, Phyllis A ^c   Kulkarni, Aniket ^b   Marchbanks, Polly A ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST FEEDING; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTRACEPTION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LIFETIME OVULATORY CYCLE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MENARCHE; MENSTRUAL CYCLE; OVARY CANCER; PARITY; PRIORITY JOURNAL; PROGNOSIS; REPRODUCTION; RISK FACTOR; UNITED STATES;

ADULT; AGE FACTORS; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; MENARCHE; MIDDLE AGED; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REPRODUCTIVE HISTORY; SEER PROGRAM; UNITED STATES; YOUNG ADULT;

EID: 67650395592     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0156     Document Type: Article

References (37)

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2002 Incidence and Mortality. Washington, DC and Atlanta, Georgia: Department of Health and Human Services, Centers for Disease Control and Prevention, and the National Cancer Institute, 2007.
2. Dicker RC, Webster LA, Layde PM, et al. Oral contraceptive use and the risk of ovarian cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA 1983;249:1596-9.
3. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990;43:559-68.
4. Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol 1991;134:362-9.
5. Moorman PG, Schilkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control 2002;13:807-11.
6. Pelucchi CS, Galeone C, Renato T, et al. Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol 2007;196:83.e1-7.
7. Purdie DM, Siskind V, Bain CJ, Webb PM, Green AC. Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 2001;153:860-4.
8. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16:30-5.
9. Tung K-H, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003;158:629-38.
10. Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer. Int J Cancer 2003;104:228-32.
11. Nagle CM, Bain CJ, Green AC, Webb PM. The influence of reproductive and hormonal factors on ovarian cancer survival. Int J Gynecol Cancer 2007;18:407-13.
12. Kjæbye-Thygesen A, Frederiksen K, Hødall CK, Blaakær J, Kjær SK. Do risk factors for epithelial ovarian cancer have an impact on prognosis? Focus on previous pelvic surgery and reproductive variables. Eur J Gynaecol Oncol 2006;27:467-72.
13. Schildkraut JM, Halabi S, Bastos E, Marchbanks PA, McDonald JA, Berchuck A. Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. Obstet Gynecol 2000;95:119-27.
14. Jacobsen BK, Vollset SE, Kvåle G. Reproductive factors and survival from ovarian cancer. Int J Cancer 1993;54:904-6.
15. Yang L, Klint A, Lambe M, et al. Predictors of ovarian cancer survival: a population-based prospective study in Sweden. Int J Cancer 2008;123:672-9.
16. Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;82:532-7.
17. Naik R, Nordin A, Cross PA, Hemming D, De Barros LA, Monaghan JM. Risk factors in stage III epithelial ovarian cancer: previous sterilisation is an adverse independent prognostic indicator. Eur J Gynaecol Oncol 2000;21:357.
18. Lee NC, Wingo PA, Gwinn ML, et al. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-5.
19. Wingo PA, Ory HW, Layde PM, Lee NC. The evaluation of the data collection process for a multicenter, population-based, case-control design. Am J Epidemiol 1988;128:206-17.
20. Marchbanks PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol 2000;95:255-60.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
22. Cox D. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
23. Barnholtz-Sloan JS, Morris R, Malone JM, Jr., Munkarah AR. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecol Oncol 2004;93:506-12.
24. Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstetr Gynecol 2003;102:156-61.
25. Ries LA. Ovarian cancer. survival and treatment differences by age. Cancer 1993;71 Suppl 2:524-9.
26. Chan J, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1,411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-6.
27. Pieretti M, Hopenhayn-Rich C, Khattar NH, Cao Y, Huang B, Tucker TC. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002;20:11-23.
28. Moorman PG, Calingaert B, Palmieri RT, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 2008;167:1059-69.
29. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971;298:163.
30. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86.
31. Bu S-Z, Yin D-L, Ren X-H, et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997;79:1944-50.
32. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1997;89:932-8.
33. Hartmann L, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12:64-9.
34. Hatcher RA. Depo-provera injections, implants, and progestin-only pills (minipills). In: Hatcher RA, Trussel J, Stewart F, et al., editors. Contraceptive technology. New York: Ardent Media, Inc.; 2004; p. 461-94.
35. Shuk-Mei H. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003;1:8.
36. Yu S, Lee M, Shin S, Park J-S. Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. J Cell Biochem2001;82:445-51.
37. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda (MD): National Cancer Institute; 2008.